Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004 – 2010

Bibliography

• Sattentau QJ, Moore JP. The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci 1993;342:59-66
   PubMed Web of Science ®Google Scholar
• Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol 1999;7:144-49
   PubMed Web of Science ®Google Scholar
• Callahan LN, Phelan M, Mallinson M, Norcross MA. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991;65:1543-50
   PubMed Web of Science ®Google Scholar
• Dey B, Lerner DL, Lusso P, Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000;74:4562-69
   PubMed Web of Science ®Google Scholar
• Rusconi S, Moonis M, Merrill DP, Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996;40:234-36
   PubMed Web of Science ®Google Scholar
• Huang L, Chen CH. Molecular targets of anti-HIV-1 triterpenes. Curr Drug Targets Infect Disord 2002;2:33-6
   PubMedGoogle Scholar
• Mastrolorenzo A, Maresca A, Rusconi S, Supuran CT. Update on the development of HIV entry inhibitors. Future HIV Ther 2008;2:479-507
   Google Scholar
• De Clercq E. Targets and strategies for the antiviral chemotherapy of AIDS. Trends in Pharmacol Sci 1990;11:198-205
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Israel RJ, Lowy I, Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004;48:423-29
   PubMed Web of Science ®Google Scholar
• Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-93
   PubMed Web of Science ®Google Scholar
• De Clercq E. Molecular targets for antiviral agents. J Pharmacol Exp Ther 2001;297:1-10
   PubMed Web of Science ®Google Scholar
• Singh IP, Chauthe SK. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 – 2010. Expert Opin Ther Patents 2011;21:229-71
   Web of Science ®Google Scholar
• Wang T, Zhang Z, Wallace OB, Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236-39
   PubMed Web of Science ®Google Scholar
• Si Z, Madani N, Cox JM, Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036-41
   PubMed Web of Science ®Google Scholar
• Lin PF, Blair W, Wang T, A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013-18
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Preparation and pharmaceutical compositions of indole, azaindole and related heterocyclic 4-alkenyl piperidine amides. US7348337; 2004
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of alkene piperidine derivatives as antiviral agents useful for the treatment of HIV and AIDS. US7572810; 2007
   Google Scholar
• Bristol-Myers Squibb. Preparation of indolyl-, azaindolyl-, and related heterocyclic sulfonylureidopiperazines for treatment of HIV and AIDS. WO2004000210; 2004
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of benzothiazole antiviral agents for treating HIV infection. US7087610; 2005
   Google Scholar
• Bristol Myers Squibb. Preparation of benzothiazole antiviral agents for treating HIV infection. US20050272734; 2005
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of piperazine enamines as antiviral agents useful for the treatment of HIV and AIDS. US7504399; 2007
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of piperazine amidines as antiviral agents. US7396830; 2007
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of tetrahydrocarbolines for treatment of HIV infection and AIDS. US7449476; 2005
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of 3-(piperazin-1-yl)cyclobut-3-ene-1,2-dione derivatives as antiviral agents. US7501419; 2007
   Google Scholar
• Bristol-Myers Squibb Company. Diketo azolopiperidines and azolopiperazines as anti-HIV agents. WO2009158394; 2009
   Google Scholar
• Bristol Myers Squibb Company. Diketopiperidine derivatives as HIV attachment inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection and AIDS. WO2009158396; 2009
   Google Scholar
• Bristol Myers Squibb Company. Prodrugs based on bicyclic nitrogen-containing heterocyclic antiviral agents having substituted piperazine or piperidine rings. WO2005090367; 2005
   Google Scholar
• Bristol-Myers Squibb Company. Preparation of aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents. US7183284; 2006
   Google Scholar
• Bristol Myers Squibb Company. Methods of treating HIV infection. US2005215543; 2005
   Google Scholar
• Bristol Myers Squibb Company. Combination for the treatment of AIDS or HIV infection. WO2005102391; 2005
   Google Scholar
• Wang J, Le N, Heredia A, Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org Biomol Chem 2005;3:1781-86
   PubMed Web of Science ®Google Scholar
• Pfizer Limited. Piperazine derivatives for the treatment of HIV infections. WO2005016344; 2005
   Google Scholar
• Pfizer Limited. Piperazine and piperidine derivatives as anti-HIV agents. WO2005121094; 2005
   Google Scholar
• Pfizer, Inc. Preparation of piperazine derivatives for use in pharmaceutical compositions for the treatment of HIV infection. US2005043300; 2005
   Google Scholar
• Pfizer, Inc. Preparation of a crystalline form of 5-[[(1S)-2-((2R)-4-benzoyl-2-methylpiperazin-1-yl)-1-methyl-2-oxoethyl]oxy]-4-methoxypyridine-2-carboxylic acid methylamide for the treatment of HIV. WO2006085199; 2006
   Google Scholar
• Propharmacon, Inc. N-Aryl piperidine compounds for inhibiting HIV infection. WO2005120503; 2005
   Google Scholar
• Trimeris, Inc. Piperazine and piperidine biaryl derivatives. WO2007103456; 2007
   Google Scholar
• Lu RJ, Tucker JA, Zinevitch T, Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. J Med Chem 2007;50:6535-44
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ma L, Jiang S, Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339:213-25
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Small molecule CD4 mimetics and uses thereof. WO2010053583; 2010
   Google Scholar
• Madani N, Schon A, Princiotto AM, Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008;16:1689-701
   PubMed Web of Science ®Google Scholar
• Vermeire K, Zhang Y, Princen K, CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302:342-53
   PubMed Web of Science ®Google Scholar
• Bell TW, Anugu S, Bailey P, Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006;49:1291-312
   PubMed Web of Science ®Google Scholar
• Vermeire K, Bell TW, Choi HJ, The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003;63:203-10
   PubMed Web of Science ®Google Scholar
• Genzyme Corp. Preparation of piperidine derivatives as modulators of chemokine receptor in particular CCR5 receptor. WO2008070758; 2008
   Google Scholar
• Phytrix JV. Phyllanthus extract for prevention and/or treatment of a HIV-associated disease. EP2116253; 2009
   Google Scholar
• John Hopkins University. Combinational paradigm combating HIV, HIV/HSV, or HIV/HPV infections in humans using small molecular weight compounds from plants. WO2008088806; 2008
   Google Scholar
• Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Jiang S, Debnath AK. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Biochem Biophys Res Commun 2000;269:641-6
   PubMed Web of Science ®Google Scholar
• Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998;95:15613-17
   PubMed Web of Science ®Google Scholar
• Wild C, Oas T, McDanal C, A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-41
   PubMed Web of Science ®Google Scholar
• Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-47
   PubMed Web of Science ®Google Scholar
• Weiss CD. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev 2003;5:214-21
   PubMedGoogle Scholar
• LaBranche CC, Galasso G, Moore JP, HIV fusion and its inhibition. Antiviral Res 2001;50:95-115
   PubMed Web of Science ®Google Scholar
• Dwyer JJ, Wilson KL, Davison DK, Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104:12772-7
   PubMed Web of Science ®Google Scholar
• Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999;42:3203-9
   PubMed Web of Science ®Google Scholar
• Jiang S, Debnath AK. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem Biophys Res Commun 2000;270:153-7
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ernst JT, Hamilton AD, XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002;18:989-97
   PubMed Web of Science ®Google Scholar
• Jiang S, Lin K, Zhang L, Debnath AK. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods 1999;80:85-96
   PubMed Web of Science ®Google Scholar
• New York Blood Center. Substituted N-phenylpyrrole compounds for inhibition of HIV infection by blocking HIV entry. WO2004047730; 2004
   Google Scholar
• New York Blood Center. Compounds for inhibition of HIV infections by blocking HIV entry. US2007232684; 2007
   Google Scholar
• New York Blood Center. Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds. US20060287319; 2006
   Google Scholar
• New York Blood Center. Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds. WO2006138118; 2006
   Google Scholar
• New York Blood Center. Combination therapy of HIV fusion/entry inhibitors targeting gp41. WO2010019717; 2010
   Google Scholar
• New York Blood Center. Starch-pomegranate juice complex as an HIV entry inhibitor and topical microbicide. US20060062866; 2006
   Google Scholar
• New York Blood Center. Methods for preventing HIV-1 or HIV-2 infection. US6727240; 2004
   Google Scholar
• President and Fellows of Harvard College. HIV inhibitors. WO2008030803; 2008
   Google Scholar
• University of Southern Medical. 1″,2″,3″,7″-tetrahydrotheaflavin with anti-AIDS effects. CN101475556; 2009
   Google Scholar
• University of Southern Medical Preparation of 1″,2″,3″,7″-tetrahydrotheaflavin-3,3′-bisgallate as anti-AIDS agent. CN10147555; 2009
   Google Scholar
• Secretary of the Department of Health and Human Services of United States. Methods for inhibiting HIV and other viral infections by modulating ceramide metabolism. WO2005072091; 2005
   Google Scholar